Measuring cognition and brain volume in people with mild cognitive impairment and Alzheimer's disease

Measures of spatial navigation and cholinergic basal forebrain degeneration in older adults with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611001168943

Enrollment

Registered

2011-11-08

Start date

2012-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The overall purpose of this study is to develop magnetic resonance imaging methods to measure degeneration of brain regions and to validate new cognitive tools for early diagnosis of Alzheimer's disease. We expect that people in the control group will perform better on the cognitive tasks than people in the mild cognitive impairment and Alzheimer's disease groups (Part A). We also expect that people's performance on the cognitive tasks will be correlated with their brain volume as measured by the MRI (Part B) and that people's MRI screens will be predictive of Alzheimer's disease diagnosis (Part C).

Interventions

Participation will include filling out a brief background information sheet and taking part in a clinical/cognitive test battery (Study Part A) and brain imaging (Study Part B). Clinical/cognitive test battery will take approximately 1 to 1.5 hours to complete and it will include the following: - Addenbrookes Cognitive Examination - Computerised spatial navigation task - Computerised spatial attention task Brain Imaging will include the Magnetic Resonance Imaging (both structural and diffusion) and it will take a total of 30 minutes to complete. Participants will be expected to complete these tasks (cognitive/clinical tasks and MRIs) only once, however, they can choose whether they would like to complete them as part of one session or to divide the participation over two sessions. Further, participants can choose to participate in either Study Part A or Study Part B, or both. This study will continue until all participants have been tested.

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Diagnosis of Mild Cognitive Impairment or mild Alzheimer's disease Fluent in written and spoken English MMSE score should be equal to or greater than 19

Exclusion criteria

MMSE score below 19 The eligible participants will be deemed healthy

Outcome results